ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas Wilms Tumor and Other Rare Tumors | NYU Langone Health

ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas Wilms Tumor and Other Rare Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Refractory Sarcomas, Wilms Tumor, And Other Rare Tumors
Age: Between 2 years - 30 years
Gender: Male or Female

Other Inclusion Criteria:

1. Patients must have recurrent or refractory disease, or newly diagnosed disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life 2. Patients must have radiographically measurable disease. 3. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

You may not be eligible for this study if the following are true:

1. Previous treatment with XL184 (cabozantinib) or another MET/HGF inhibitor (tivantinib, crizotinib) 2. Patients who are currently receiving another investigational drug are not eligible. 3. Anti-cancer Agents: Patients who are currently receiving other anticancer agents are not eligible.